– Identified and prospectively replicated an EEG-based biomarker for placebo response in MDD – – New data strengthen the mechanistic link between ALTO-300 and the EEG biomarker being used for patient selection; biomarker signature induced by activating 5-HT2C or depleting dopamine directly – – Preclinical ALTO-101 rescue study underscores the therapeutic potential of this novel PDE4 inhibitor, and validates EEG theta response as a robust translational biomarker for CIAS – Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced multiple presentations at t

Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company management team will present at the JonesResearch Virtual CNS Day on Tuesday, April 29, 2025, at 12:30 pm ET and participate in one-on-one investor meetings. The presentation will be accessible via a live webcast on the Events and Presentations page in the Investors section of Alto's website and a replay will be available following the presentation. About Alto Neuroscience Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine psychiat

– Favorable outcome from interim analysis of ongoing ALTO-300 Phase 2b MDD trial; topline results expected in mid-2026 – – Completed enrollment in ALTO-203 Phase 2 proof-of-concept MDD trial; on track to report topline data in the second quarter of 2025 – – Novel transdermal formulation of ALTO-101 demonstrated greater drug exposure and improved tolerability profile; topline data from Phase 2 trial of ALTO-101 in schizophrenia expected in the second half of 2025 – – Company's precision psychiatry approach underpins recently granted patents covering the use of ALTO-100 and ALTO-300 in biomarker defined populations – – Strong cash position of approximately $169 million expected to fund pl

SINGAPORE, March 13, 2025 /PRNewswire/ -- High-Trend International Group (NASDAQ:HTCO) (the "Company"), an international shipping company, today announced the appointment of Christopher Nixon Cox, as Chairman of the Company, effective immediately. Mr. Cox , a venture capitalist and advocate for socially impactful investing, will leverage his extensive expertise in global markets and sustainability to drive the Company's strategic growth in innovation-driven sectors. Mr. Jinyu Chang resigned as Chairman while remaining a director of the Company. The Company also named Mr. Bo Cui as its new Chief Legal Officer, underscoring its commitment to strengthening governance and global compliance amid

Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company management team will present at the following upcoming investor conferences and events in March: TD Cowen 45th Annual Health Care Conference, March 3-5th 2025: Format: Presentation and one-on-one investor meetings Presentation Date/Time: Tuesday, March 4, 2025, at 9:50 am ET Location: Marriott Copley Place, Boston, MA Leerink's Global Healthcare Conference 2025, March 10-12th 2025: Format: Presentation and one-on-one investor meetings Presentation Date

– Patent supports Alto's precision approach to improve patient selection – Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that the U.S. Patent and Trademark Office has granted U.S. Patent Number 12,226,375, with method claims pertaining to treatment of major depressive disorder (MDD) in patients with inadequate response to an antidepressant. The method includes treatment with ALTO-300 as an adjunctive therapy and patient selection using specific electroencephalogram (EEG) measures. As granted, not accounting for any potential patent term extension

– Interim analysis resulted in a recommendation to continue the study with a total targeted biomarker population of ~200 patients in the final analysis sample – – Topline results are expected in mid-2026 – – The company recently reported an estimated preliminary 2024 year-end cash balance of approximately $168 million, which is expected to support planned operations into 2028 – Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced a favorable outcome from the planned interim analysis for the Phase 2b trial of ALTO-300 as an adjunctive treatment for

– Data generated from Alto's precision psychiatry platform and clinical-stage product candidates highlighted across three poster presentations and a panel discussion – – New preclinical data from a reverse translation study demonstrates the link between the mechanism of ALTO-300 and the EEG biomarker used for patient selection – – An interim analysis will be conducted for the ongoing Phase 2b trial of ALTO-300 as an adjunctive treatment in MDD; results from the interim analysis are expected in the first quarter of 2025, followed by topline data from the complete study sample in the first half of 2025 – Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO) a clinical-stage biopharmaceutical com

– Topline data from two MDD trials expected in the first half of 2025: Phase 2b trial of ALTO-300 as an adjunctive treatment and Phase 2a trial of ALTO-203 in patients with anhedonia – – Additional Phase 2 studies ongoing: ALTO-101 in schizophrenia and ALTO-100 as an adjunctive treatment in bipolar depression – – Key learnings from ALTO-100 Phase 2b MDD trial including clinically meaningful effect observed in a pre-specified secondary analysis and evidence of stratification using the pre-specified enrichment biomarker in patients with confirmed drug compliance – – Strong cash position of approximately $182 million is expected to fund planned operations into 2027, and through at least

Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company management team will present at the following upcoming investor conferences and events in November: Stifel 2024 Healthcare Conference, November 18-19th 2024: Format: Fireside chat and one-on-one investor meetings Presentation Date/Time: Monday, November 18, 2024, at 3:00 pm ET Location: Lotte New York Palace, New York Jefferies London Healthcare Conference, November 19-21st 2024: Format: Fireside chat and one-on-one investor meetings Presentation Date/Time:

SC 13G/A - Alto Neuroscience, Inc. (0001999480) (Subject)

SC 13G - Alto Neuroscience, Inc. (0001999480) (Subject)

SC 13G - Alto Neuroscience, Inc. (0001999480) (Subject)

SC 13G - Alto Neuroscience, Inc. (0001999480) (Subject)

Wedbush downgraded Alto Neuroscience from Outperform to Neutral and set a new price target of $4.00 from $29.00 previously

Rodman & Renshaw downgraded Alto Neuroscience from Buy to Neutral

Wedbush initiated coverage of Alto Neuroscience with a rating of Outperform and set a new price target of $29.00

William Blair initiated coverage of Alto Neuroscience with a rating of Outperform

TD Cowen initiated coverage of Alto Neuroscience with a rating of Outperform

Robert W. Baird initiated coverage of Alto Neuroscience with a rating of Outperform and set a new price target of $32.00

Jefferies initiated coverage of Alto Neuroscience with a rating of Buy and set a new price target of $33.00

Stifel initiated coverage of Alto Neuroscience with a rating of Buy and set a new price target of $32.00

4 - Alto Neuroscience, Inc. (0001999480) (Issuer)

4 - Alto Neuroscience, Inc. (0001999480) (Issuer)

4 - Alto Neuroscience, Inc. (0001999480) (Issuer)

4 - Alto Neuroscience, Inc. (0001999480) (Issuer)

4 - Alto Neuroscience, Inc. (0001999480) (Issuer)

4 - Alto Neuroscience, Inc. (0001999480) (Issuer)

4 - Alto Neuroscience, Inc. (0001999480) (Issuer)

4 - Alto Neuroscience, Inc. (0001999480) (Issuer)

4 - Alto Neuroscience, Inc. (0001999480) (Issuer)

3 - Alto Neuroscience, Inc. (0001999480) (Issuer)

DEFA14A - Alto Neuroscience, Inc. (0001999480) (Filer)

DEF 14A - Alto Neuroscience, Inc. (0001999480) (Filer)

S-8 - Alto Neuroscience, Inc. (0001999480) (Filer)

10-K - Alto Neuroscience, Inc. (0001999480) (Filer)

8-K - Alto Neuroscience, Inc. (0001999480) (Filer)

SCHEDULE 13G/A - Alto Neuroscience, Inc. (0001999480) (Subject)

SCHEDULE 13G/A - Alto Neuroscience, Inc. (0001999480) (Subject)

SCHEDULE 13G/A - Alto Neuroscience, Inc. (0001999480) (Subject)

8-K - Alto Neuroscience, Inc. (0001999480) (Filer)

EFFECT - Alto Neuroscience, Inc. (0001999480) (Filer)

4 - Alto Neuroscience, Inc. (0001999480) (Issuer)

4 - Alto Neuroscience, Inc. (0001999480) (Issuer)

SINGAPORE, March 13, 2025 /PRNewswire/ -- High-Trend International Group (NASDAQ:HTCO) (the "Company"), an international shipping company, today announced the appointment of Christopher Nixon Cox, as Chairman of the Company, effective immediately. Mr. Cox , a venture capitalist and advocate for socially impactful investing, will leverage his extensive expertise in global markets and sustainability to drive the Company's strategic growth in innovation-driven sectors. Mr. Jinyu Chang resigned as Chairman while remaining a director of the Company. The Company also named Mr. Bo Cui as its new Chief Legal Officer, underscoring its commitment to strengthening governance and global compliance amid

– Mr. Hanley brings over two decades of leadership experience in product development and commercialization across a wide range of neuropsychiatric indications, including major depressive disorder and schizophrenia – Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO) today announced the expansion of the Company's leadership team with the addition of industry veteran Michael Hanley as chief operating officer (COO). Mr. Hanley brings over twenty-five years of leadership experience in the life sciences industry, with established expertise across corporate operations, product development, strategy, and commercialization, with relevant expertise in CNS/neuroscience-focused companies. As Alto's COO, M

– Experienced Medical and Executive Leader, Dr. Radhakrishnan served as Group SVP and Chief Medical Officer of Biogen, responsible for the Worldwide Medical function – Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO) today announced the appointment of Maha Radhakrishnan, M.D. to the company's board of directors. Dr. Radhakrishnan is an accomplished industry executive with decades of experience advancing large strategic portfolios across different therapeutic areas through product development and commercialization and overseeing the global medical strategy and operations within major biotechnology and pharmaceutical companies. "Maha joins our Board at a pivotal moment for Alto, as we continu